CEL-SCI is expanding its phase III trial of the investigational therapy Multikine to four additional European countries: Spain, the Czech Republic, Slovakia, and Croatia.
These countries were selected because they have a high incidence of head and neck cancer, as well as the required facilities and scientific and technical personnel with the necessary experience for running the phase III study, the company said.
The Multikine study is currently being run in eight countries, including the U.S. The study is designed to determine if Multikine therapy administered prior to the current standard of care -- surgery plus radiotherapy or surgery plus concurrent radiochemotherapy -- for treating patients with head and neck cancer will result in an increased overall rate of survival.
